• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Evofem Biosciences Inc.

    9/9/25 4:05:22 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EVFM alert in real time by email
    DEFA14A 1 formdefa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
       
    ☐  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ☐ Definitive Proxy Statement
       
    ☐ Definitive Additional Materials
       
    ☒ Soliciting Material Under Rule 14a-12

     

    EVOFEM BIOSCIENCES, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required.
       
    ☐ Fee previously paid with preliminary materials.
       
    ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     

     

    Evofem Anticipates Approval of Merger with Aditxt at

    Upcoming Stockholder Meeting

     

    — Special Meeting to be held on September 26, 2025 —

     

    SAN DIEGO, CA, September 9, 2025 — In an update to stockholders today, Evofem Biosciences, Inc. (“Evofem” or the “Company”) (OTCID: EVFM) anticipates the approval of the transactions (the “Merger”) contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the “Merger Agreement”), with Aditxt, Inc. (Nasdaq: ADTX) and Adifem, Inc., a wholly-owned subsidiary of Aditxt, at the Company’s Special Meeting of Stockholders (the “Special Meeting”) to be held on September 26, 2025.

     

    CEO Saundra Pelletier noted, “We have support agreements in place with the holders of Series E-1 and G-1 sufficient to approve the Merger. In addition, we also have strong support from other key investors, giving us confidence that the Merger will be approved at our Special Meeting later this month.”

     

    The key proposal to be voted at the Special Meeting seeks stockholder approval of the Merger. If approved by at least a majority of the combined voting power of common stock, Series E-1 and G-1, and assuming all closing conditions are met, at close Adifem will merge with and into Evofem, with Evofem surviving as a wholly owned subsidiary of Aditxt, forming the core of a dedicated women’s health program within Aditxt’s social innovation platform accelerating promising health innovations.

     

    As set forth in the definitive proxy materials (the “Definitive Proxy”) filed with the U.S. Securities and Exchange Commission on September 8, 2025, in connection with the Special Meeting, there were 118,656,354 shares of Evofem’s common stock issued and outstanding as of August 26, 2025, which is the record date for the Special Meeting. The holders of Series E-1 and G-1 have 13.87% and 39.84%, respectively and in aggregate, of the Evofem combined voting power. Collectively, the voting power of these shares equates to 53.71% of combined voting power. No assurance can be provided that the holders of Series E-1 and G-1 will vote as agreed or that the conditions to closing will be performed or satisfied or that the transactions contemplated by the Merger Agreement will occur.

     

    “Evofem is committed to empowering women by delivering innovation in sexual and reproductive healthcare. We believe we will be better positioned to successfully execute this mission and accelerate our growth trajectory with access to potentially greater resources and opportunities as a subsidiary of Aditxt. We therefore ask our stockholders to vote “for” the Merger at the Special Meeting of Stockholders on September 26th,” added Ms. Pelletier.

     

     

     

     

    About Evofem Biosciences

     

    Evofem is commercializing innovative products to address unmet needs in women’s sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products.

     

    PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information.

     

    SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information.

     

    PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.

     

    Evofem filed a Definitive Proxy on September 8, 2025, for the Special Meeting of Stockholders to be held on Friday, September 26, 2025, at which stockholders of record will be asked to consider and vote on a proposal to approve the transactions contemplated under the Merger Agreement between the Company, Aditxt, Inc. (NASDAQ: ADTX) and Adifem, Inc., a wholly owned subsidiary of Aditxt. Pursuant to the Merger Agreement, Adifem will merge with and into the Company, with Evofem surviving as a wholly owned subsidiary of Aditxt. The closing of the transactions contemplated by the Merger Agreement is subject to conditions including, but not limited to, approval of the transactions by a majority of the combined voting power of Evofem’s Series E-1, Series G-1 and common stock, voting together as a single class, the affirmative vote of holders of a majority of each of the Series E-1 and G-1, Aditxt raising sufficient capital to fund its closing obligations, and other customary closing conditions.

     

    For additional information regarding the proposals to be acted upon at the upcoming Special Meeting, please refer to Evofem’s Definitive Proxy, which is available free of charge through the SEC’s website at https://www.sec.gov/ix?doc=/Archives/edgar/data/0001618835/000164117225026774/formdefm14a.htm

     

    BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE DEFINITIVE PROXY, AS IT CONTAINS IMPORTANT INFORMATION REGARDING THE MATTERS TO BE CONSIDERED AT THE SPECIAL MEETING. STOCKHOLDERS WITH QUESTIONS ARE ENCOURAGED TO CONTACT THE COMPANY AT [email protected]

     

     

     

     

    Forward-Looking Statements

     
    This press release includes “forward-looking statements,” within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, “anticipate,” “aim,” “believe,” “confidence”, “contemplate,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “suggest,” “strategy,” “target,” “will,” “would,” and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to Evofem’s beliefs that the Series E-1 and G-1 stockholders will vote FOR the Merger, that the Company will be better positioned to successfully execute its mission and accelerate its growth trajectory as a subsidiary of Aditxt, and that it may have access to potentially greater resources and opportunities as a subsidiary of Aditxt. No assurance can be given that the conditions to closing will be performed or satisfied or that the transactions contemplated by the Merger Agreement will occur.

     

    You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company’s SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 14, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law.

     

    Connect With Us

     

    Media

     

    [email protected]

     

    Investors and Potential Partners

     

    Amy Raskopf, Chief Business Development Officer

    Evofem Biosciences, Inc.

    [email protected]

    (917) 673-5775

     

    Join the Dialogue

     

    LinkedIn @evofem + @saundrapelletier
    TikTok @phexxi + @saundrapelletier
    Instagram @evofem, @phexxi + @saundrapelletier
    X @evofem + @SaundraCEO
    Facebook @evofem + @phexxi

     

    ###

     

     

     

     

     

    Get the next $EVFM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EVFM

    DatePrice TargetRatingAnalyst
    3/4/2022$0.50 → $0.53Underweight
    Morgan Stanley
    11/16/2021$2.50 → $2.00Buy
    HC Wainwright & Co.
    10/21/2021$4.00 → $2.50Buy
    HC Wainwright & Co.
    10/14/2021$0.80Equal-Weight → Underweight
    Morgan Stanley
    8/12/2021$3.00 → $1.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $EVFM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Evofem Biosciences with a new price target

    Morgan Stanley reiterated coverage of Evofem Biosciences with a rating of Underweight and set a new price target of $0.53 from $0.50 previously

    3/4/22 8:06:41 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Evofem Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.00 from $2.50 previously

    11/16/21 9:42:11 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Evofem Biosciences with a new price target

    HC Wainwright & Co. reiterated coverage of Evofem Biosciences with a rating of Buy and set a new price target of $2.50 from $4.00 previously

    10/21/21 6:49:27 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting

    -- Special Meeting to be held on September 26, 2025 -- SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions (the "Merger") contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the "Merger Agreement"), with Aditxt, Inc. (NASDAQ:ADTX) and Adifem, Inc., a wholly-owned subsidiary of Aditxt, at the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on September 26, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.

    9/9/25 9:28:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law

    -- Passage of House Bill 3489 allows Illinois pharmacists to prescribe non-hormonal and emergency contraceptives -- -- Ensures a broader range of contraceptive choices is available to women state-wide -- SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- On August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation permits pharmacists to prescribe a wider array of contraceptive options, including PHEXXI® (lactic acid, citric acid, and potassium bitartrate) , the hormone-free on-demand contraceptive vaginal gel from Evofem Biosciences (OTCID: EVFM). The law is slated to take effect on January 1, 2026.

    8/21/25 8:56:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

    -- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)">

    8/19/25 9:39:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    SEC Filings

    View All

    SEC Form DEFA14A filed by Evofem Biosciences Inc.

    DEFA14A - Evofem Biosciences, Inc. (0001618835) (Filer)

    9/9/25 4:05:22 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFM14A filed by Evofem Biosciences Inc.

    DEFM14A - Evofem Biosciences, Inc. (0001618835) (Filer)

    9/5/25 6:46:04 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PREM14A filed by Evofem Biosciences Inc.

    PREM14A - Evofem Biosciences, Inc. (0001618835) (Filer)

    8/26/25 5:23:30 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Zhang Yan sold $4 worth of shares (104 units at $0.04), closing all direct ownership in the company (SEC Form 4)

    4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

    1/12/24 5:13:24 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kamdar Kim P. sold $6 worth of shares (10 units at $0.62), closing all direct ownership in the company (SEC Form 4)

    4 - Evofem Biosciences, Inc. (0001618835) (Issuer)

    12/22/23 4:05:30 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 5 filed by File Justin J.

    5 - Evofem Biosciences, Inc. (0001618835) (Issuer)

    5/8/23 4:05:19 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Leadership Updates

    Live Leadership Updates

    View All

    Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune™

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced that Dr. Charles Howe, Chair of the Division of Experimental Neurology and Director of Research at the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology, will join the Aditxt Weekly Update on May 2, 2025, to discuss key findings from the newly announced preclinical study evaluating ADI-100™, the lead therapeutic candidate developed by its wholly owned subsidiary, Adimune™, Inc. ("Adimune"). Featured participants will include Dr. Shahrokh Shabahang, Chief Innovation Officer of Aditxt, Inc., and Dr. Friedrich Kapp, Co-Chief Executive Offic

    4/17/25 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sylvia Hermina Joins Aditxt's Board of Directors, Elevating Leadership with Broader Perspectives

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to its Board of Directors. With over 20 years of experience advising public companies on corporate governance, mergers and acquisitions, and shareholder relations, Ms. Hermina brings a wealth of expertise in fostering effective and impactful engagement between management teams and stakeholders. Throughout her career, Ms. Hermina has advised NYSE and NASDAQ listed companies on governance best practices and developed communication strategies tailored to retail and institutional investors. As Senior Vice

    10/29/24 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aditxt's Precision Health Subsidiary, Pearsanta, Appoints Christopher Mitton as President as it Seeks to Complete Clinical Validation Studies for its Mitomic® Endometriosis Test (MET™) and Mitomic® Prostate Test (MPT™)

    Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ:ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), appointed Christoper Mitton as President. Christopher Mitton brings over 20 years of leadership experience in the medical diagnostics industry, with a strong focus on personalized healthcare and molecular oncology diagnostics. He has a proven track record in building and leading successful commercial operations, underpinned by his deep expertise in product commercialization, business development, and strategic sales and marketing. Mr. Mitton continues to serve as

    8/26/24 8:15:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $EVFM
    Financials

    Live finance-specific insights

    View All

    Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update

    -- Increased Net Sales and Improved Loss from Operations in Q2 2025 vs. Prior Year Quarter -- -- Evofem Advances Plans for Special Meeting of Stockholders to Approve the A&R Merger Agreement and Become a Wholly-owned Subsidiary of Aditxt --  SAN DIEGO, Aug. 14, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Bioscienc

    8/14/25 8:46:00 AM ET
    $ADTX
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Reports First Quarter 2025 Financial Results and Provides Business Update

    SAN DIEGO, May 15, 2025 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCPK: EVFM), today announced financial results for the first quarter ended March 31, 2025. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> "Quarterly fluctuations are normal for our business, which is why we focus on driving annual growth," said Saundra Pelletier, Evofem's CEO. "First quarter net sales were soft, as expected, due to the high level of PHEXXI stocking orders in the fourth qua

    5/15/25 7:59:00 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Windtree Therapeutics Reports Year-End 2024 Financial Results and Provides Key Business Updates

    WARRINGTON, Pa., April 15, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the fiscal year ended December 31, 2024 and provided key business updates. "The year 2024 saw Windtree make great progress in many key areas including clinical development of our lead drug candidate istaroxime in cardiogenic shock, business development and the future strategy of the Company," said Jed Latkin, CEO of Windtree. "Cardiogenic shock is a critical condition with high morbidity and mortality where clinician

    4/15/25 8:00:00 AM ET
    $EVFM
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $EVFM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    2/14/24 2:14:48 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    2/14/23 11:24:47 AM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Evofem Biosciences Inc. (Amendment)

    SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)

    8/10/22 4:17:03 PM ET
    $EVFM
    Biotechnology: Pharmaceutical Preparations
    Health Care